title: Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
authors.forename: Ganesh
authors.initials: G
authors.lastname: Raghu
authors.forename: Harold R
authors.initials: HR
authors.lastname: Collard
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Anstrom
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Flaherty
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Fleming
authors.forename: Talmadge E
authors.initials: TE
authors.lastname: King
authors.forename: Fernando J
authors.initials: FJ
authors.lastname: Martinez
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Brown
mesh_terms: D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D023381:Endpoint Determination / Q000379:methods*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy*; D019141:Respiratory System Agents / Q000627:therapeutic use*
chemical_list: D019141:Respiratory System Agents